Table 3 NCCN and ESMO guidelines for... | American Society of Hematology

Table 3

NCCN and ESMO guidelines for NLPHL

	Stage
Guideline	IA, no risk factors⁴⁰	IB	IIA	IIB	III/IV A	III/IV B
NCCN guidelines, version 2.2013³⁹ (all category 2A unless otherwise indicated)	Observe* or ISRT	CHT ± rituximab ± ISRT	Observe or ISRT	CHT ± rituximab ± ISRT	CHT ± rituximab ± RT or observation† or local RT‡	CHT ± rituximab ± RT
ESMO⁴⁰	IFRT	CHT ± IFRT	CHT ± IFRT	CHT ± IFRT	CHT	CHT

	Stage
Guideline	IA, no risk factors⁴⁰	IB	IIA	IIB	III/IV A	III/IV B
NCCN guidelines, version 2.2013³⁹ (all category 2A unless otherwise indicated)	Observe* or ISRT	CHT ± rituximab ± ISRT	Observe or ISRT	CHT ± rituximab ± ISRT	CHT ± rituximab ± RT or observation† or local RT‡	CHT ± rituximab ± RT
ESMO⁴⁰	IFRT	CHT ± IFRT	CHT ± IFRT	CHT ± IFRT	CHT	CHT

CHT, chemotherapy (for details see reference).

Option for completely excised solitary lymph node

Category 2B

Palliation only